Zhi Tong Cai Jing·2025-09-26 09:36Core Viewpoint - Fosun Pharma (600196.SH) announced plans to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, intends to establish a special fund with a cash contribution of RMB 54.6 million alongside Hongyi Tianjin and Zhonghui Life Insurance, aiming for a 9.98% share in the fund after full fundraising [1] - The subsidiary plans to transfer the 100% equity of Shanghai Clone and related debts to the special fund or its controlled entities for no more than RMB 1.256 billion, following the establishment of the fund and fulfillment of agreed conditions [1] - Post-transaction, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - Proceeds from the transfer will be allocated to the ongoing investment in the group's innovative drug business [1]